Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Queensland Health
Deloitte
Teva
Merck
Cipla
McKesson
QuintilesIMS
Johnson and Johnson
Covington

Generated: August 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,383,471 protect, and when does it expire?


Patent ► Subscribe protects CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: ► Subscribe

Title: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
Abstract:The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compositions by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compositions of the invention are particularly suitable for use in oral dosage forms.
Inventor(s): Chen; Feng-Jing (Salt Lake City, UT), Patel; Mahesh V. (Salt Lake City, UT)
Assignee: Lipocine, Inc. (Salt Lake City, UT)
Application Number:09/287,043
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Delivery; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Spriaso Llc
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE
chlorpheniramine maleate; codeine phosphate
TABLET, EXTENDED RELEASE;ORAL206323-001Jun 22, 2015DISCNNoNo► Subscribe► SubscribeY TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)0059475► Subscribe
European Patent Office1165048► Subscribe
Canada2366702► Subscribe
Australia3763700► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Moodys
US Department of Justice
Healthtrust
Citi
Fish and Richardson
Colorcon
QuintilesIMS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot